News

Genzyme Releases

December 9, 2009	Genzyme Laboratory Recognized for Quality
December 8, 2009	Genzyme’s Mozobil Shows Promise in Chemosensitization
December 3, 2009	Genzyme to Reopen Enrollment in Alglucosidase Alfa Temporary Access Program
November 17, 2009	Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHA
November 16, 2009	Genzyme Receives Complete Response Letter on Lumizyme Application
October 21, 2009	Genzyme Reports Third-Quarter Financial Results
October 20, 2009	First Patient Enrolled in Phase 3 Trials of Genzyme Oral Capsule for Gaucher Disease
October 6, 2009	Genzyme Receives FDA Complete Response Letter for Clolar
August 10, 2009	Genzyme Provides Update on Cerezyme Supply and 2009 Financial Information
July 22, 2009	Genzyme Delivers Solid Second-Quarter Financial Results
June 12, 2009	Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease
June 2, 2009	Genzyme Completes Transaction with Bayer HealthCare
March 2, 2009	Genzyme Receives Complete Response Letter from FDA on Lumizyme Application
February 26, 2009	European Authorities Approve Larger-Scale Production of Genzyme’s Myozyme
February 19, 2009	Genzyme Receives Positive Opinion on Myozyme from CHMP
October 15, 2008	Genzyme Begins Enrollment in Post-Marketing Study to Evaluate Use of Low Dose Fabrazyme Treatment for Fabry Disease
September 23, 2008	Mozobil Receives Priority Review with FDA Action Expected by Year End; Synvisc-ONE FDA Action also Expected by Year End

Terms and Conditions of Use | Privacy Policy | © 2002-2012 Genzyme Corporation, a Sanofi company. All rights reserved.